A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable
hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All
patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society